



Consolidated Financial Statements for the Year Ended March 31, 2022
FY2022 (April 1, 2021 – March 31, 2022) [UNAUDITED]

May 12, 2022

Company name: Takara Bio Inc.
 Stock exchange listings: Tokyo Stock Exchange
 Code number: 4974
 URL: <https://www.takara-bio.co.jp>
 Company representative: Koichi Nakao, President & CEO
 Contact: Takuya Kakemi, Executive Officer, Head of Corporate Management Division
 Tel. (077) 565-6970

Scheduled date of general shareholder's meeting: June 24, 2022
 Scheduled date of starting delivery of dividends: June 27, 2022
 Scheduled date of annual securities report filing date: June 29, 2022
 Supplementary documents of the financial results: Yes
 Financial results briefing: Yes

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
 2. Amounts are rounded down to the nearest million yen.

1. Results for the year ended March 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)

(1) Consolidated operating results

(Percentages indicate changes from the same period of the previous fiscal year.)

	Year ended Mar. 31, 2022		Year ended Mar. 31, 2021	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	67,699	46.9	46,086	33.3
Operating profit	28,902	107.1	13,952	122.4
Ordinary profit	28,459	101.0	14,159	123.1
Net income (loss) attributable to owners of parent	19,849	107.9	9,547	149.9
Net income per share (in yen)	164.84		79.29	
Fully diluted net income per share (in yen)	-		-	
Return on equity		23.3		13.6
Ratio of ordinary profit to total assets		27.7		17.2
Ratio of operating profit to net sales		42.7		30.3
(Note) Comprehensive income	23,689	173.1	8,674	169.7

(2) Consolidated financial position

	As of Mar. 31, 2022	As of Mar. 31, 2021
	(Millions of yen)	(Millions of yen)
Total assets	115,712	89,750
Net assets	96,064	74,302
Equity ratio (%)	82.9	82.7
Net assets per share (in yen)	796.18	616.05
(Reference) Equity	95,873	74,181

(3) Consolidated cash flow

	As of Mar. 31, 2022	As of Mar 31, 2021
	(Millions of yen)	(Millions of yen)
Cash flow from operating activities	6,985	13,943
Cash flow from investing activities	(7,071)	(3,778)
Cash flow from financing activities	(2,070)	(1,103)
Cash and cash equivalent, end year	22,160	23,308

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

2. Dividends

	Annual dividends per share in yen		
	Year ended Mar. 31, 2021	Year ended Mar. 31, 2022	Year ending Mar. 31, 2023 (Forecast)
First quarter end	-	-	-
Second quarter end	0.00	0.00	0.00
Third quarter end	-	-	-
Year end	16.00	33.00	33.00
Annual	16.00	33.00	33.00
Total dividend (Millions of Yen)	1,926	3,973	
Payout ratio (%)	20.2	20.0	37.5
Dividend on equity (%)	2.7	4.7	

3. Forecast for the year ending March 31, 2023 (Apr. 1, 2022 – Mar. 31, 2023)

(Percentages indicate year-on-year changes for the full year and year-on-year changes for the quarter.)

	Six months ending Sep. 30, 2022		Year ending Mar. 31, 2023	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	27,744	(12.1)	55,300	(18.3)
Operating profit	8,641	(38.7)	15,000	(48.1)
Ordinary profit	8,726	(38.7)	15,100	(46.9)
Net income attributable to owners of the parent	6,354	(36.5)	10,600	(46.6)
Net income per share (in yen)	52.77		88.03	

※ Others

(1) Changes in subsidiaries during the period

(Changes in specified subsidiaries resulting in change of scope) : No

Newly included: – (Name)

Excluded: – (Name)

(2) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: Yes

2) Changes in accounting policies other than 1): No

3) Changes in accounting estimates: No

4) Restatement: No

NOTE: For details, please refer to "(5) Notes to Consolidated Financial Statements (Changes in Accounting Policies)" of "3. Consolidated Financial Statements and Primary Notes" on page 11 of the attached material.

(3) Number of outstanding shares (Common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of March 31, 2022 120,415,600

As of March 31, 2021 120,415,600

2) Number of treasury stocks at year end

As of March 31, 2022 -

As of March 31, 2021 -

3) Average number of outstanding shares

As of March 31, 2022 120,415,600

As of March 31, 2021 120,415,600

(Reference) Summary of Non-consolidated Financial Results

1. Non-consolidated results for the year ended March 31, 2022 (April 1, 2021 – March 31, 2022)

(1) Non-consolidated Results of Operations

	Year ended Mar. 31, 2022		Year ended Mar. 31, 2021	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	50,398	48.7	33,885	54.1
Operating profit	21,931	126.3	9,693	266.4
Ordinary profit	25,063	118.0	11,495	186.8
Net income	18,485	112.9	8,681	230.9

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

Net income per share (in yen)	153.51	72.10
Fully diluted net income per share (in yen)	-	-

(2) Non-consolidated Financial Position

	As of Mar. 31, 2022	As of Mar 31, 2021
	(Millions of yen)	(Millions of yen)
Total assets	101,386	81,124
Net assets	86,204	69,645
Equity ratio (%)	85.0	85.9
Net assets per share (in yen)	715.89	578.38
(Reference) Equity	86,204	69,645

<Reasons for the difference from the results of the previous fiscal year for the non-consolidated results>

In the fiscal year under review, due to strong sales of Reagents and CDMO, we have experienced a difference between the actual results for the previous fiscal year and the actual results for the fiscal year under review.

※ These financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Inc. (the “Company”) based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to “1. Overview of Financial Results (4) Future Outlook on page 2 of the attached document.

The Company will hold a briefing for institutional investors and analysis on Tuesday, May 17, 2022. The material handed out at this briefing and a review of questions and answers will be posted on our website after the briefing.

Contents of the attached document

1. Overview of Financial Results for the year ended March 31, 2022.....	2
(1) Overview of Financial Results.....	2
(2) Overview of Financial Position.....	2
(3) Overview of Cash Flows.....	2
(4) Future Outlook.....	2
2. Basic Concept on Selection of Accounting Standards.....	4
3. Consolidated Financial Statements and Primary Notes.....	5
(1) Consolidated Balance Sheets.....	5
(2) Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income.....	7
(Consolidated Statements of Profit or Loss).....	7
(Consolidated Statements of Comprehensive Income).....	8
(3) Consolidated Statements of Change in Net Assets.....	9
(4) Consolidated Statements of Cash Flows	10
(5) Notes to Consolidated Financial Statements.....	11
(Notes on Premise of Going Concern)	11
(Significant Accounting Estimates).....	11
(Changes in Accounting Policies).....	11
(Changes in Presentation Methods).....	11
(Additional Information).....	11
(Segment Information).....	12
(Per Share Information).....	12
(Significant Subsequent Events).....	12
4. Supplementary Information.....	13
(1) Trends in Key Indicators for Business Management.....	13
(2) Comparative Consolidated Statement of Income	14
(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts.....	15

1. Overview of Financial Results for the year ended March 31, 2022

(1) Overview of Financial Results

The outlook for the global economy in the fiscal year under review is uncertain due to the impact of the new Coronavirus disease (COVID-19), the prolonged trade friction between the U.S. and China, and Russia's invasion of Ukraine.

Under these circumstances, Takara Bio Group is promoting initiatives to advance the development of fundamental biologics development technologies and become a biologics development company that continuously creates new modalities through the Reagents and Instruments and CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal 2026, and the three-year Medium-Term Management Plan FY2023, which ends in fiscal 2023¹. In addition, the Group worked aggressively to ensure a stable supply of PCR test-related products for the new Corona Virus and to establish a manufacturing system for regenerative medicine products, including vaccines.

In the fiscal year under review, although sales of Instruments and Gene Therapy decreased year on year, sales of Reagents and CDMO increased year on year. In particular, sales of reagents for general research recovered from the Corona crisis, resulting in record-high sales, and PCR testing-related reagents for the new Coronavirus also recorded substantial growth. Net sales increased to ¥67,699 million (up 46.9% year on year), and the cost of sales ratio improved. As a result, the cost of sales increased to ¥18,488 million (up 30.1% year on year), resulting in a gross profit of ¥49,211 million (up 54.4% year on year). Selling, general and administrative (SG&A) expenses were ¥20,309 million (up 13.3% year on year), mainly due to an increase in personnel expenses and R&D expenses. Operating profit was ¥28,902 million (up 107.1% year on year).

As a result of the increase in operating profit, ordinary profit increased to ¥28,459 million (up 101.0% year on year), income before income taxes and others increased to ¥27,532 million (up 103.1% year on year), and net income attributable to owners of the parent increased to ¥19,849 million (up 107.9% year on year).

Since our group is a single segment, the disclosure by segment is omitted.

(2) Overview of Financial Position

Total assets at the end of the fiscal year under review were ¥115,712 million, an increase of ¥25,962 million from the end of the previous fiscal year. This was mainly due to an increase of ¥13,999 million in merchandise and finished goods and an increase of ¥5,218 million in trade receivables, and an increase of ¥6,629 million in property, plant and equipment mainly due to interior finish work for a new office building in Takara Bio USA, Inc. and our manufacturing facilities acquisitions.

Total liabilities at the end of the fiscal year under review were ¥19,647 million, an increase of ¥4,199 million from the end of the previous fiscal year. This was mainly due to increase of ¥2,352 million in accrued income taxes and ¥1,531 million in accrued payable-other.

Total net assets at the end of the fiscal year under review were ¥96,064 million, an increase of ¥21,762 million from the end of the previous fiscal year. This was mainly due to increases of ¥17,923 million in retained earnings and ¥3,737 million in foreign currency translation adjustment due to the yen's depreciation.

(3) Overview of Cash Flows

Net cash provided by operating activities amounted to ¥6,985 million, a decrease of ¥6,958 million from the previous fiscal year. This was mainly due to cash inflow from income before income taxes and minority interests of ¥27,532 million and depreciation and amortization of ¥3,554 million, and cash outflow from an increase in inventories of ¥14,233 million, income taxes paid of ¥5,922 million, and an increase in trade receivables of ¥4,812 million.

Net cash used in investing activities was ¥7,071 million, an increase of ¥3,292 million from the previous fiscal year. This was mainly due to proceeds from withdrawal of time deposits of ¥12,877 million, purchase of property, plant and equipment and intangible assets of ¥12,403 million, payments into time deposits of ¥11,406 million, and subsidies received of ¥3,960 million.

Net cash used in financing activities amounted to ¥2,070 million, an increase of ¥966 million from the previous fiscal year, mainly due to cash dividends paid of ¥1,923 million.

As a result of the above, the balance of cash and cash equivalents at the end of the fiscal year under review, including the effect of exchange rate changes on cash and cash equivalents, decreased by ¥1,148 million from the end of the previous fiscal year to ¥22,160 million.

(4) Future Outlook

Over the next fiscal year, sales are expected to decrease overall due to a decrease in demand for PCR testing-related reagents for the new Coronavirus. In addition, operating income and ordinary income are expected to decrease from the previous fiscal year

¹ FY2026 and FY2023 refer to the fiscal year ending March 31, 2026 and 2023, respectively.

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

due to plans to increase personnel expenses, R&D expenses, etc. in selling, general and administrative (SG&A) expenses.

As a result, we forecast net sales of ¥55,300 million, operating profit of ¥15,000 million, ordinary profit of ¥15,100 million, and net income attributable to owners of parent of ¥10,600 million.

See "4. Supplementary Information (3) Comparative Statement of Income Relating to Consolidated Results Forecasts" on page 15 for a comparison of the following consolidated financial year forecasts with the results for the year ended March 31, 2022.

In addition, the forecast for the next fiscal year is based on the assumption that the impact of the COVID-19 will continue for a certain period in fiscal 2022, and may fluctuate depending on circumstances. The Company will promptly disclose any necessary revisions to its earnings forecasts.

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

2. Basic Concept on Selection of Accounting Standards

The Group prepares its consolidated financial statements in accordance with Japanese GAAP, considering the comparability of consolidated financial statements between periods and between companies.

With regard to the application of IFRS, the Company's policy is to respond appropriately, taking into account various domestic and overseas circumstances.

3. Consolidated Financial Statements and Primary Notes

(1) Consolidated Balance Sheets

(Millions of yen)

	As of Mar. 31, 2021	As of Mar. 31, 2022
Assets		
Current assets		
Cash and deposits	25,993	23,633
Notes and accounts receivable-trade	12,626	-
Notes receivable-trade	-	466
Electronically recorded monetary claims-operating	-	1,231
Accounts receivable-trade	-	16,147
Merchandise and finished goods	4,966	18,966
Work in process	1,316	1,361
Raw materials and supplies	2,901	3,738
Other	1,352	2,637
Allowance for doubtful accounts	(41)	(40)
Total current assets	49,115	68,141
Non-current assets		
Property, plant and equipment		
Buildings and structures	15,670	23,553
Accumulated depreciation	(5,147)	(5,937)
Buildings and structures, net	10,522	17,615
Machinery, equipment and vehicles	7,058	7,626
Accumulated depreciation	(3,760)	(4,147)
Machinery, equipment and vehicles, net	3,297	3,479
Tools, furniture and fixtures	7,673	9,530
Accumulated depreciation	(5,141)	(5,516)
Tools, furniture and fixtures, net	2,531	4,014
Land	8,143	8,413
Leased assets	771	756
Accumulated depreciation	(87)	(125)
Leased assets, net	684	631
Construction in progress	3,756	1,519
Others	1,025	855
Accumulated depreciation	(194)	(161)
Others, net	830	723
Total Property, plant and equipment	29,766	36,395
Intangible assets		
Goodwill	6,149	6,309
Technology-based intangible assets	1,953	1,523
Other	1,270	1,326
Total intangible assets	9,373	9,159
Investments and other assets		
Deferred tax assets	1,075	1,539
Retirement benefit assets	114	123
Others	305	352
Total investments and other assets	1,495	2,015
Total non-current assets	40,635	47,571
Total assets	89,750	115,712

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

(Millions of yen)

	As of Mar. 31, 2021	As of Mar. 31, 2022
Liabilities		
Current liabilities		
Notes and accounts payable-trade	2,077	1,959
Lease obligations	138	137
Accrued payable-other	2,911	4,443
Accrued income taxes	3,146	5,498
Provision	739	923
Other	4,177	4,418
Total current liabilities	13,191	17,380
Non-current liabilities		
Lease obligations	1,003	910
Deferred tax liabilities	-	198
Retirement benefit liabilities	800	788
Other	452	370
Total non-current liabilities	2,256	2,266
Total liabilities	15,448	19,647
Net assets		
Shareholders' equity		
Share capital	14,965	14,965
Capital surplus	32,893	32,893
Retained earnings	27,085	45,009
Total shareholders' equity	74,945	92,868
Accumulated other comprehensive income		
Foreign currency translation adjustment	(529)	3,208
Cumulative remeasurements of retirement benefit	(234)	(204)
Total accumulated other comprehensive income	(763)	3,004
Non-controlling interests	120	191
Total net assets	74,302	96,064
Total liabilities and net assets	89,750	115,712

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

(2) Consolidated Statements of Profit or Loss and Consolidated Statements of Comprehensive Income

(Consolidated Statements of Profit or Loss)

(Millions of yen)

	Year ended Mar. 31, 2021	Year ended Mar. 31, 2022
Net sales	46,086	67,699
Cost of sales	14,214	18,488
Gross profit	31,872	49,211
SG&A expenses		
Provision for doubtful accounts	17	20
Employees' salaries and bonuses	4,577	5,327
Provision for accrued bonuses	424	528
Retirement benefit expenses	191	230
R&D expenses	5,545	6,109
Other	7,163	8,093
Total SG&A expenses	17,919	20,309
Operating profit	13,952	28,902
Non-operating income		
Interest income	113	122
Foreign exchange gains	2	-
Rent income from real estate	128	141
Other	63	94
Total non-operating income	308	357
Non-operating expenses		
Interest expenses	24	23
Foreign exchange loss	-	706
Rent expenses on real estate	54	61
Other	21	8
Total non-operating expenses	101	800
Ordinary profit	14,159	28,459
Extraordinary gains		
Gain on sale of fixed assets	1	6
National subsidies	517	4,470
Total extraordinary profit	518	4,476
Extraordinary losses		
Loss on disposal of fixed assets	99	174
Asset shrinkage losses	517	4,470
Loss of valuation of inventory	-	589
Impairment loss	-	168
Loss on liquidation of business	458	-
Others	50	-
Total extraordinary losses	1,125	5,403
Profit before income taxes and others	13,552	27,532
Income taxes-current	4,297	7,901
Income taxes-deferred	(326)	(277)
Total income taxes	3,971	7,624
Net income	9,581	19,908
Net income attributable to non-controlling interest	34	58
Net income attributable to owners of the parent	9,547	19,849

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

(Consolidated Statements of Comprehensive Income)

(Millions of yen)

	Year ended March 31, 2021	Year ended March 31, 2022
Net income	9,581	19,908
Other comprehensive income		
Foreign currency translation adjustment	(974)	3,751
Remeasurements of retirement benefit	66	29
Total other comprehensive income	(907)	3,781
Comprehensive income	8,674	23,689
Comprehensive income attributable to:		
Owners of the parent	8,648	23,617
Non-controlling interest	25	71

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

(3) Consolidated Statements of Changes in Net Assets

Previous fiscal year (from April 1, 2020 to March 31, 2021)

(Millions of yen)

	Shareholders' equity				Accumulated other comprehensive income			Non-Controlling interest	Total net assets
	Share Capital	Capital surplus	Retained earnings	Total shareholders' equity	Foreign currency translation adjustment	Cumulative remeasurements of retirement benefit	Total accumulated other comprehensive income		
Balance at the beginning of current period	14,965	32,893	18,501	66,360	436	(300)	135	95	66,591
Change of items during the period									
Dividends from surplus			(963)	(963)					(963)
Net income attributable to owners of the parent			9,547	9,547					9,547
Net changes of items other than shareholders' equity					(965)	66	(898)	25	(873)
Total changes of items during the period	-	-	8,584	8,584	(965)	66	(898)	25	7,710
Balance at the end of current period	14,965	32,893	27,085	74,945	(529)	(234)	(763)	120	74,302

Current fiscal year (from April 1, 2021 to March 31, 2022)

(Millions of yen)

	Shareholders' equity				Accumulated other comprehensive income			Non-controlling interests	Total net assets
	Share Capital	Capital surplus	Retained earnings	Total shareholders' equity	Foreign currency translation adjustment	Cumulative remeasurements of retirement benefit	Total accumulated other comprehensive income		
Balance at the beginning of current period	14,965	32,893	27,085	74,945	(529)	(234)	(763)	120	74,302
Changes of items during the period									
Dividends from surplus			(1,926)	(1,926)					(1,926)
Net income attributable to owners of the parent			19,849	19,849					19,849
Net changes of items other than shareholders' equity					3,737	29	3,767	71	3,839
Total changes of items during the period	-	-	17,923	17,923	3,737	29	3,767	71	21,762
Balance at the end of current period	14,965	32,893	45,009	92,868	3,208	(204)	3,004	191	96,064

(4) Consolidated Statements of Cash Flows

(Millions of yen)

	Year ended Mar. 31, 2021	Year ended Mar. 31, 2022
Net cash provided by (used in) operating activities		
Income before income taxes and others	13,552	27,532
Depreciation and amortization	3,220	3,554
Impairment loss	-	168
Depreciation and amortization on other	80	95
Amortization of goodwill	486	500
Increase (decrease) in allowance for doubtful accounts	(14)	(3)
Increase (decrease) in reserve for bonuses	190	144
Increase (decrease) in retirement benefit liabilities	16	(12)
Interest income	(113)	(122)
Interest expenses	24	23
Loss (gain) on sale and retirement of fixed assets	97	168
Loss on liquidation of business	458	-
Decrease (increase) in trade receivables	(3,559)	(4,812)
Decrease (increase) in inventories	(1,767)	(14,233)
Increase (decrease) in notes and accounts payable-trade	1,016	(431)
Increase (decrease) in other current liabilities	2,416	81
Others	(573)	(526)
Subtotal	15,533	12,127
Interest and dividend income received	107	133
Income expenses paid	(24)	(23)
Income taxes paid	(1,854)	(5,922)
Subsidies received	181	671
Net cash provided by (used in) operating activities	13,943	6,985
Net cash provided by (used in) investing activities		
Payments into time deposits	(2,613)	(11,406)
Proceeds from withdrawal of time deposits	3,766	12,877
Proceeds from sales and redemption of securities	2,000	-
Purchase of property, plant and equipment and intangible assets	(8,687)	(12,403)
Proceeds from sales of property, plant and equipment and intangible assets	14	47
Purchase of other depreciable assets	(158)	(136)
Subsidies received	1,900	3,960
Others	(0)	(10)
Net cash provided by (used in) investing activities	(3,778)	(7,071)
Net cash provided by (used in) financing activities		
Dividends paid	(962)	(1,923)
Repayments of lease obligations	(140)	(147)
Net cash provided by (used in) financing activities	(1,103)	(2,070)
Effect of exchange rate change on cash and cash equivalents	(215)	1,008
Net increase (decrease) in cash and cash equivalents	8,845	(1,148)
Cash and cash equivalents at beginning of period	14,462	23,308
Cash and cash equivalents at end of period	23,308	22,160

(5) Notes to Consolidated Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Significant Accounting Estimates)

(Goodwill)

Our group recorded goodwill at Takara Bio USA, Inc., which was recorded in the past upon the acquisition of all of the shares of Clontech Laboratories, Inc., Rubicon Genomics, Inc. and WaferGen Bio-systems, Inc., respectively.

(1) Amounts recorded in the consolidated financial statements for the current fiscal year

(Millions of yen)

	Current Consolidated Fiscal Year
Goodwill	6,309

(2) Information on the content of critical accounting estimates for identified items

Takara Bio USA, Inc. determines as a reporting unit, including goodwill, and performs procedures to determine indicators of impairment. The recoverable amount of the reporting unit is based on its fair value. Fair value is determined primarily based on the discounted present value of estimated future cash flows, which utilize assumptions such as future growth rates to estimate such cash flows.

As the recoverable amount sufficiently exceeds the carrying amount at the end of the fiscal year under review, the Company considers that it is unlikely that a material impairment loss will occur even if there is a reasonable range of changes in future growth rates and other factors used in the calculation of the recoverable amount.

(Changes in Accounting Policies)

(Application of Accounting Standard for Revenue Recognition)

The Company adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020, hereinafter referred to as the "Revenue Recognition Accounting Standard") from the beginning of the fiscal year under review and recognized revenue when control of promised goods or services is transferred to customers in an amount that is expected to be received in exchange for those goods or services.

With regard to the application of the Revenue Recognition Accounting Standards, in accordance with the transitional treatment stipulated in the provisions of paragraph 84 of the Accounting Standard for Revenue Recognition, the cumulative effect of retrospective application of a new accounting policy prior to the beginning of the fiscal year under review has been adjusted to retained earnings at the beginning of the fiscal year under review, and a new accounting policy has been applied from the beginning of the fiscal year under review.

In addition, "Notes and accounts receivable-trade," which was presented in "Current assets" in the consolidated balance sheets for the previous fiscal year, is included in "Notes receivable-trade," "Electronically recorded monetary claims-operating," and "Accounts receivable-trade" from the current fiscal year. However, in accordance with the transitional treatment set forth in paragraph 89-2 of the Accounting Standard for Revenue Recognition, no reclassifications have been made to the prior fiscal year under the new presentation method.

As a result, there was no impact on profit or loss for the current fiscal year. In addition, there is no impact on the balance of retained earnings at the beginning of the fiscal year.

(Change in Presentation Method)

Statement of Profit or Loss

(Non-operating expenses)

"Costs of idle fixed assets" under non-operating expenses, which had been stated separately in the previous fiscal year, has been included in "Other" from the fiscal year under review, as the amount has become immaterial.

To reflect this change in presentation, the consolidated financial statements for the previous fiscal year have been reclassified.

As a result, ¥18 million, which was presented as "Costs of idle fixed assets" under non-operating expenses in the consolidated statements of income for the previous fiscal year, has been reclassified as "Other."

(Additional Information)

(Accounting Estimates for the Impact of the COVID-19)

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

Based on information available at the time of preparation of the consolidated financial statements for the fiscal year under review, it is assumed that the impact of the COVID-19 on our Group will continue for a certain period in fiscal 2022. The Company makes estimates and judgments regarding the impairment of goodwill and the recoverability of deferred tax assets at the end of the fiscal year based on the assumptions described above. However, no indicators of impairment have been identified for goodwill, and the Company has determined that no additional valuation allowance is required for the recoverability of deferred tax assets.

Due to the high degree of uncertainty associated with the impact of the COVID-19, any change in the above assumptions could have an impact on the Group's financial condition and results of operations.

(Segment Information)

Since our group is a single segment, this information is omitted.

(Per-Share Information)

	End of previous fiscal year (From April 1, 2020 to March 31, 2021)	Current Consolidated Fiscal Year (From April 1, 2021 to March 31, 2022)
Net assets per share	¥616.05	¥796.18
Net income per share	¥79.29	¥164.84

(NOTE) 1. Diluted net income per share is not presented because there were no dilutive shares.

2. The basis for calculating net income per share is as follows.

	End of previous fiscal year (From April 1, 2020 to March 31, 2021)	Current Consolidated Fiscal Year (From April 1, 2021 to March 31, 2022)
Net income per share		
Profit attributable to owners of parent (Millions of yen)	9,547	19,849
Amounts not attributable to common stock (Millions of yen)	-	-
Profit attributable to owners of parent attributable to common stock (Millions of yen)	9,547	19,849
Average number of shares of common stock outstanding during the period (Thousands of shares)	120,415	120,415

(Significant Subsequent Events)

Not applicable.

The original disclosure in Japanese was released on May 12, 2022 at 15:00 (GMT+8)

4. Supplementary Information

(1) Trends in Key Indicators for Business Management

1) Cash Flows

(Millions of yen)

	Year ended Mar. 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)	Year ended Mar. 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)
Cash flow from operating activities	13,943	6,985
Cash flow from investing activities	(3,778)	(7,071)
Cash flow from financing activities	(1,103)	(2,070)

2) Sales Breakdown by Region

(Millions of yen)

	Year ended Mar. 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)	Year ended Mar. 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)
Japan	20,475	34,076
United States	7,862	10,186
China	8,415	11,908
Asia excluding Japan and China	4,917	6,614
Europe	3,743	4,668
Others	671	244
Total	46,086	67,699

3) R&D Expenses by Reportable Segment

Since our group is a single segment, this information is omitted.

(2) Comparative Consolidated Statement of Income

(Rounded down to one million yen)

	Year ended Mar. 31, 2021	Year ended Mar. 31, 2022	Y/Y Change	Y/Y Ratio
(Net sales)				
Reagents	35,189	54,605	19,416	55.2%
Instruments	1,726	1,518	(208)	(12.1%)
CDMO	8,901	11,426	2,525	28.4%
Gene therapy	268	148	(119)	(44.5%)
Total net sales	46,086	67,699	21,613	46.9%
(Operating profit and Loss)				
Net sales	46,086	67,699	21,613	46.9%
Cost of sales	14,214	18,488	4,274	30.1%
Gross profit	31,872	49,211	17,339	54.4%
SG & A expenses	17,919	20,309	2,390	13.3%
Transportation expenses	742	755	13	1.8%
Advertising expenses	57	58	0	1.4%
Promotion expenses	676	683	7	1.1%
R&D expenses	5,545	6,109	564	10.2%
Administrative expense, other	10,496	12,153	1,657	15.8%
Enterprise taxes (external standards taxation)	401	548	146	36.5%
Operating profit	13,952	28,902	14,949	107.1%
(Non-operating income and Expenses)				
Non-operating income	308	357	49	16.2%
Non-operating expenses	101	800	699	691.6%
Ordinary profit	14,159	28,459	14,299	101.0%
(Extraordinary gains & Losses)				
Extraordinary gains	518	4,476	3,957	763.2%
Extraordinary losses	1,125	5,403	4,278	380.1%
Income before income taxes and others	13,552	27,532	13,979	103.1%
Income taxes	3,971	7,624	3,653	92.0%
Net income	9,581	19,908	10,326	107.8%
Net income (loss) attributable to non-controlling interests	34	58	23	69.9%
Net income attributable to owners of the parent	9,547	19,849	10,302	107.9%
Depreciation and amortization (Property, plant and equipment and intangible assets)	3,220	3,554	334	10.4%
Amortization of goodwill	486	500	14	2.9%

※ From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents", "Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

(3) Comparative Statement of Income Relating to Consolidated Financial Forecasts

(Rounded down to one million yen)

	Year ended Mar. 31, 2022	Year ending Mar. 31, 2023 Forecast	Y/Y Change	Y/Y Ratio
(Net sales)				
Reagents	52,479	41,010	(11,468)	(21.9%)
Instruments	1,518	1,471	(47)	(3.1%)
CDMO	11,426	10,212	(1,214)	(10.6%)
Gene therapy	2,275	2,606	331	14.6%
Total Net Sales	67,699	55,300	(12,399)	(18.3%)
(Operating profit and Loss)				
Net sales	67,699	55,300	(12,399)	(18.3%)
Cost of sales	18,488	17,444	(1,044)	(5.6%)
Gross profit	49,211	37,855	(11,355)	(23.1%)
SG & A expenses	20,309	22,855	2,546	12.5%
Transportation expenses	755	748	(7)	(0.9%)
Advertising expenses	58	91	33	56.8%
Promotion expenses	683	899	215	31.5%
R&D expenses	6,109	7,820	1,711	28.0%
Administrative expenses, other	12,153	12,877	723	6.0%
Enterprise taxes (external standards taxation)	548	418	(129)	(23.6%)
Operating profit	28,902	15,000	(13,902)	(48.1%)
(Non-operating income and Expenses)				
Non-operating income	357	211	(146)	(40.8%)
Non-operating expenses	800	111	(688)	(86.0%)
Ordinary profit	28,459	15,100	(13,359)	(46.9%)
(Extraordinary gains & Losses)				
Extraordinary gains	4,476	250	(4,226)	(94.4%)
Extraordinary losses	5,403	55	(5,347)	(99.0%)
Income before income taxes and others	27,532	15,294	(12,237)	(44.4%)
Income taxes	7,624	4,648	(2,975)	(39.0%)
Net income	19,908	10,645	(9,262)	(46.5%)
Net income (loss) attributable to non-controlling interests	58	45	(12)	(21.4%)
Net income attributable to owners of parent	19,849	10,600	(9,249)	(46.6%)
Depreciation and amortization (Property, plant and equipment and intangible assets)	3,554	4,282	727	20.5%
Amortization of goodwill	500	514	14	2.8%

※ The sales of GMP-grade reagents and the resembling which are used for manufacturing regenerative medicine products included in “Reagents” until the year ended of March 31, 2022 have been included in “Gene therapy” since the year ending March 31, 2023. The results for the year ended March 31, 2022 in this table have been reclassified to reflect these changes.